Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Arch Immunol Ther Exp (Warsz). 2012 Feb;60(1):31-41. doi: 10.1007/s00005-011-0152-z. Epub 2011 Dec 6.
Hematopoietic cell transplantation (HCT) offers potentially curative therapy for patients with myelodysplastic syndrome (MDS). However, as the majority of patients with MDS is in the 7th or 8th decade of life, only few of these patients were transplanted following high-dose conditioning regimens. The development of reduced-intensity conditioning has allowed to apply HCT also to older patients and those with clinically relevant comorbid conditions. Dependent upon disease status and the type of clonal chromosomal abnormalities present at the time of HCT, some 25-75% of patients will be cured of their disease and survive long term. Recent results with HLA-matched unrelated donors are comparable to those with HLA genotypically identical siblings. The increasing use of cord blood and HLA-haploidentical donors is expected to make HCT available to a growing number of patients. However, post-transplant relapse and graft-versus-host disease remain problems requiring further instigations.
造血细胞移植（HCT）为骨髓增生异常综合征（MDS）患者提供了潜在的治愈性治疗。然而，由于大多数 MDS 患者处于 70 或 80 岁以上的年龄段，只有少数这些患者接受了大剂量预处理方案的移植。减量化预处理方案的发展使得 HCT 也可以应用于年龄较大的患者和有临床相关合并症的患者。根据疾病状态以及移植时存在的克隆染色体异常的类型，约 25-75%的患者将治愈疾病并长期存活。最近 HLA 匹配的无关供者的结果与 HLA 基因型相同的同胞供者的结果相当。脐带血和 HLA 半相合供者的使用越来越多，预计将使越来越多的患者能够接受 HCT。然而，移植后复发和移植物抗宿主病仍然是需要进一步研究的问题。
